Evaluating the role of PET/CT imaging in managing advanced cervical cancer after treatment
Evaluation of the Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer at an Advanced Stage. Multicenter Prospective Observational Study
University Hospital, Brest · NCT04008095
This study is trying to see if using PET/CT scans after treatment helps doctors make better decisions for patients with advanced cervical cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University Hospital, Brest (other) |
| Locations | 2 sites (Brest and 1 other locations) |
| Trial ID | NCT04008095 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the impact of post-therapy 18F-FDG PET/CT imaging on the clinical management of patients with advanced cervical cancer. It will involve a multicenter approach, comparing clinician decisions made without PET/CT results to those made with the imaging results available. The study will focus on patients who have undergone treatment for locally advanced cervical cancer and will evaluate the therapeutic implications of the imaging within two months post-treatment. The goal is to clarify the prognostic value of PET/CT in guiding further management decisions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with locally advanced cervical cancer (FIGO stages IB3 to IVA) who are eligible for curative treatment.
Not a fit: Patients with other types of tumors, those who are minors, pregnant or breastfeeding, or who have contraindications to MRI and PET/CT will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management strategies for patients with advanced cervical cancer, leading to improved outcomes.
How similar studies have performed: Previous studies have indicated the prognostic value of PET/CT imaging in cervical cancer management, but this specific approach is still under evaluation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient old ≥ 18 years * Uterine cervical cancer with locally-advanced (FIGO 2019 IB3 to IVA) * Histology: squamous cell carcinoma and adenocarcinoma * Feasibility of a curative treatment * Having formulated a non-opposition Exclusion Criteria: * Minor patient \< 18 years * Pregnancy or breastfeeding * Other type of tumor than squamous cell carcinoma and adenocarcinoma * FIGO 2019 \< IB3 or \> IVA * Non-eligibility for the examination * Contraindication to MRI and PET/CT * Previous history of cancer * Refusal of participation
Where this trial is running
Brest and 1 other locations
- CHRU de Brest (Hôpital Morvan) — Brest, France (RECRUITING)
- Centre Henri Becquerel — Rouen, France (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Alexandra LE DUC-PENNEC
- Email: alexandra.leduc-pennec@chu-brest.fr
- Phone: +33 2 98 22 31 19
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cervical Cancer, cervical cancer, pet/ct, post-therapeutic, advanced stage, management